Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.62 +0.58%

+$0.04 today

Market cap
$3.04B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.56M

Average 1.66M

Returns on capital

Xeris Biopharma Holdings, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

4.0%

avg -36.3%

ROIC

8.9%

avg -48.0%

ROA

0.1%

avg -42.5%

Analysis

ROIC is currently the strongest return metric at 8.9% versus its period average of -48.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

John Shannon

Chairman & CEOUSD 1.36M64——

Kevin McCulloch

President & Chief Operating OfficerUSD 913.53K621.56M0.90%

Beth Hecht

Chief Legal Officer & Corporate SecretaryUSD 817.37K621.09M0.63%

Steven Pieper

Chief Financial OfficerUSD 796.18K491.35M0.78%

Anh Nguyen

Chief Medical OfficerUSD 653.7K51——

Joshua Bennett

Vice President of Strategy & Business Development————

Brian Conner

SVP of Quality and Chief Compliance & Risk Officer————

Allison Wey

Senior Vice President of Investor Relations & Corporate Communications————

Kendal Korte

Senior Vice President of Human Resources————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

35

$5.83M

Net Transaction Value

−$5.83M

Net selling

Most Active

Hecht Beth

13 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 5, 26

McCulloch Kevin

Direct

Sell$312.2K
Nov 2, 26

Hecht Beth

Direct

Sell$255.8K
Nov 2, 26

McCulloch Kevin

Direct

Sell$153.5K
Nov 2, 26

Pieper Steven

Direct

Sell$51.2K
Oct 1, 26

Pieper Steven

Direct

Sell$47K
Oct 1, 26

McCulloch Kevin

Direct

Sell$141.1K
Oct 1, 26

Hecht Beth

Direct

Sell$156.8K
Sep 28, 26

McCulloch Kevin

Direct

Sell$250K
Sep 1, 26

McCulloch Kevin

Direct

Sell$127.3K
Sep 1, 26

Hecht Beth

Direct

Sell$141.4K

1–10 of 35

Summary

Insiders reported 0 buys worth $0.00 and 35 sells worth $5.83M over the last 12 months. That adds up to net selling of $5.83M. Hecht Beth was the most active insider with 13 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+230.7% (5yr)2 analysts
RevenueN/AN/A+38.3%
+25.2% (5yr)3 analysts
Net IncomeN/AN/AN/A
+230.5% (5yr)3 analysts
EBITN/AN/AN/A
+65.2% (5yr)3 analysts

Analysis

Recent growth has been strongest in Revenue at +38.3% over three years. Forward estimates point to EPS at +230.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Xeris Biopharma Holdings, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about XERS's management, answered from reported figures.

Who manages XERS?

Xeris Biopharma Holdings, Inc. (XERS) lists 9 active executives. The top listed executive is Anh Nguyen, Chief Medical Officer.

Are XERS insiders buying or selling?

Recent insider activity shows net buying of $1.37M.